ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL MIXED CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL MIXED CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL MIXED CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for aggressive uterine cancer: targeted combo shows promise in phase 3 trial
Disease control Recruiting nowThis study tests whether adding two targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can shrink tumors and stop HER2-positive endometrial cancer from coming back. About 360 people with stage I to IV cancer will receive either chemo alone or chemo plus the targ…
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:57 UTC
-
New hope for aggressive endometrial cancer: drug combo targets obesity link
Disease control Recruiting nowThis early-stage trial is testing the safety of combining two drugs, atezolizumab and ONC201, for people with advanced or recurrent endometrial cancer. The study includes both obese and non-obese participants to see how body weight affects treatment. The goal is to find the best …
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:54 UTC
-
Immunotherapy duo shows promise against tough uterine cancer
Disease control Recruiting nowThis study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against one drug alone (nivolumab) to see which shrinks tumors better. About …
Matched conditions: ENDOMETRIAL MIXED CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:56 UTC